Fig 2.

50% Neutralization titers (Neut50) in undepleted (A) and Heterologous virus-depleted (B) baseline seronegative subjects vaccinated with one dose of TDV (left) or after exposure to primary DV1 or DV2 infection (right). The TDV vaccine cohort included sera from 30 subjects collected 180 days after TDV vaccination. The primary infection cohort included 6 primary DENV1 and 8 primary DENV2, collected at baseline in study DEN-205. Each sample was BSA-depleted (Undepleted control) (A) or depleted of cross-reactive nAbs using heterologous serotype viruses (HET Depleted) (B). To measure DV1 and DV3 TS neutralization, HET depletion was done with a mix of DV2+DV4 dynabeads. For DV2 and DV4 TS titers, Het depletion was done with a mix of DV1+DV3 dynabeads. Each value represents the titer after subtraction of background homologous depletion titer. Each dot represents one subjects. Line represents the GMT of the Neut50 titers. The # of subjects with evidence of TS nAbs >20 after HET depletion/#total subjects analyzed is shown at the bottom of panel B. % TS is the percent of subjects with TS nAbs = or > 20. The lowest serum dilution tested was 20 (horizontal dotted line). Statistical analysis was done using nonparametric Friedman test for multiple comparison among serotypes after TDV vaccine. ** P < 0,005; **** P < 0.0001.